It has been found that in tumor immunity, CD4+ T cells can activate CD8+ T cells through a variety of mechanisms, allowing them to differentiate into CTL while maintaining and enhancing the anti-tumor response of CTL. This evidence concerns the gene CD4 and neoplasm.